

Immudex MHC I & MHC II Monomers

Superior quality and broad selection of ready-to-use
and peptide-receptive monomers

RUO and GMP available



Phosphoinositide 3-Kinase δ Regulates Dectin-2 Signaling and the Generation of Th2 and Th17 Immunity

This information is current as
of March 5, 2022.

Min Jung Lee, Eri Yoshimoto, Shinobu Saijo, Yoichiro Iwakura, Xin Lin, Howard R. Katz, Yoshihide Kanaoka and Nora A. Barrett

J Immunol 2016; 197:278-287; Prepublished online 18 May 2016;

doi: 10.4049/jimmunol.1502485

<http://www.jimmunol.org/content/197/1/278>

Supplementary Material <http://www.jimmunol.org/content/suppl/2016/05/18/jimmunol.1502485.DCSupplemental>

References This article **cites 57 articles**, 25 of which you can access for free at:
<http://www.jimmunol.org/content/197/1/278.full#ref-list-1>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>



Phosphoinositide 3-Kinase δ Regulates Dectin-2 Signaling and the Generation of Th2 and Th17 Immunity

Min Jung Lee,^{*,†} Eri Yoshimoto,^{*,†} Shinobu Saijo,[‡] Yoichiro Iwakura,[§] Xin Lin,[¶] Howard R. Katz,^{*,†} Yoshihide Kanaoka,^{*,†} and Nora A. Barrett^{*,†}

The C-type lectin receptor Dectin-2 can trigger the leukotriene C₄ synthase-dependent generation of cysteinyl leukotrienes and the caspase-associated recruitment domain 9- and NF- κ B-dependent generation of cytokines, such as IL-23, IL-6, and TNF- α , to promote Th2 and Th17 immunity, respectively. Dectin-2 activation also elicits the type 2 cytokine IL-33, but the mechanism by which Dectin-2 induces these diverse innate mediators is poorly understood. In this study, we identify a common upstream requirement for PI3K δ activity for the generation of each Dectin-2-dependent mediator elicited by the house dust mite species, *Dermatophagoides farinae*, using both pharmacologic inhibition and small interfering RNA knockdown of PI3K δ in bone marrow-derived dendritic cells. PI3K δ activity depends on spleen tyrosine kinase (Syk) and regulates the activity of protein kinase C δ , indicating that PI3K δ is a proximal Syk-dependent signaling intermediate. Inhibition of PI3K δ also reduces cysteinyl leukotrienes and cytokines elicited by Dectin-2 cross-linking, confirming the importance of this molecule in Dectin-2 signaling. Using an adoptive transfer model, we demonstrate that inhibition of PI3K δ profoundly reduces the capacity of bone marrow-derived dendritic cells to sensitize recipient mice for Th2 and Th17 pulmonary inflammation in response to *D. farinae*. Furthermore, administration of a PI3K δ inhibitor during the sensitization of wild-type mice prevents the generation of *D. farinae*-induced pulmonary inflammation. These results demonstrate that PI3K δ regulates Dectin-2 signaling and its dendritic cell function. *The Journal of Immunology*, 2016, 197: 278–287.

Dectin-2 is a myeloid C-type lectin receptor (CLR) with well-described roles in antifungal immunity (1, 2). Upon activation with hyphae from *Candida albicans*, Dectin-2 triggers the generation of NF- κ B-dependent inflammatory cytokines IL-6, IL-10, IL-23, and TNF- α and the development of Th17 immunity (3). Dectin-2 has a short cytoplasmic tail, but it pairs with the ITAM-bearing FcR γ -chain to initiate Src homology region 2 domain-containing phosphatase 2- and spleen tyrosine kinase (Syk)-dependent signaling (3–5). The downstream activation and nuclear translocation of NF- κ B by Dectin-2, and by several other CLRs, requires the protein kinase C δ (PKC δ)-dependent

phosphorylation of the adaptor protein caspase-associated recruitment domain (CARD)9 (6) and its assembly with B cell lymphoma/leukemia 10 and MALT lymphoma translocation protein 1 (7). Inhibition of MALT lymphoma translocation protein 1 abrogates Th17 immunity to *Candida* (8), which is in keeping with the importance of the Dectin-2/CARD9 pathway in the generation of Th17 immunity.

Dectin-2 activation can also elicit Th2-dependent pulmonary inflammation through the immediate generation of proinflammatory lipid mediators, cysteinyl leukotrienes (cys-LTs). Cys-LTs are derived from membrane arachidonate through the serial actions of cytosolic phospholipase A₂, 5-lipoxygenase in the presence of the 5-lipoxygenase activating protein, and LTC₄ synthase (LTC₄S) (9–11). Dectin-2-dependent cys-LT generation is elicited by glycans from common aeroallergens, including *Aspergillus fumigatus* and the house dust mite (HDM) species *Dermatophagoides farinae* and *Dermatophagoides pteronyssinus* (12). Dectin-2-dependent arachidonate metabolism in macrophages can also be triggered by *C. albicans* (13), suggesting it is a central feature of Dectin-2 signaling. Whereas Dectin-2 signaling is required for the generation of both Th2 and Th17 allergic pulmonary inflammation elicited by HDM (14–16), the Dectin-2/LTC₄S pathway in dendritic cells (DCs) is required only for Th2 immunity to HDM through the autocrine actions of cys-LTs at the type 1 cys-LT receptor (14).

HDM-elicited allergic pulmonary inflammation also requires the type 2 cytokine IL-33, which promotes sensitization to HDM through the ST2-dependent upregulation of OX40L on lung DCs (17, 18). Notably, HDM can elicit IL-33 generation in bone marrow-derived DCs (BMDCs) through a Dectin-2- and PI3K-dependent pathway (19), suggesting that IL-33 production may be a second Dectin-2-dependent autocrine signal that conditions DCs for Th2 immunity. However, the mechanism by which Dectin-2 controls the generation of these diverse mediators remains poorly understood.

Class I PI3Ks catalyze the phosphorylation of phosphatidylinositol at the 3-position to generate second messengers in response

*Department of Medicine, Harvard Medical School, Boston, MA 02115; [†]Jeff and Penny Vinik Center for Allergic Disease Research, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA 02115; [‡]Division of Molecular Immunology, Medical Mycology Research Center, Chiba University, Chiba 260-8673, Japan; [§]Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba 278-0022, Japan; and [¶]Department of Molecular and Cellular Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030

ORCID: 0000-0003-0194-6845 (E.Y.).

Received for publication November 25, 2015. Accepted for publication April 27, 2016.

This work was supported by National Institutes of Health Grants T32 AI007306-27, U19 AI095219, R21 AI107425, R01 HL120952, and K08 AI 080948, and by generous contributions from the Vinik Family and the Kaye Family.

Address correspondence and reprint requests to Dr. Nora A. Barrett, Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, Smith Building, Room 628A, One Jimmy Fund Way, Boston, MA 02115. E-mail address: nbarrett@partners.org

The online version of this article contains supplemental material.

Abbreviations used in this article: Akt, protein kinase B; BAL, bronchoalveolar lavage; BMDC, bone marrow-derived dendritic cell; CARD, caspase-associated recruitment domain; CLR, C-type lectin receptor; cys-LT, cysteinyl leukotriene; DC, dendritic cell; EGFP, enhanced GFP; HDM, house dust mite; IRF, IFN regulatory factor; LT, leukotriene; LTC₄S, leukotriene C₄ synthase; MDLN, mediastinal lymph node; PAS, periodic acid–Schiff; PKC δ , protein kinase C δ ; PLC γ , phospholipase C γ ; siRNA, small interfering RNA; Syk, spleen tyrosine kinase; WT, wild-type.

Copyright © 2016 by The American Association of Immunologists, Inc. 0022-1767/16/\$30.00

to transmembrane signaling (20). Although the upstream signaling that activates PI3Ks is incompletely understood, YXXM-bearing receptors, G protein-coupled receptors, and rat sarcoma-dependent receptors have been implicated (21). The PI3K p110 δ isoform (PI3K δ) is highly expressed in hematopoietic cells and plays a key role in lymphocyte activation through the TCR and the BCR (22). PI3K δ is also activated by the high-affinity receptor for IgE, Fc ϵ R1, and mediates the phosphorylation of protein kinase B (Akt) and degranulation in mast cells (23, 24). As Fc ϵ R1 and Dectin-2 each uses the Fc γ -chain to initiate ITAM/Syk-dependent cys-LT generation, we sought to determine whether PI3K δ is required for Dectin-2-dependent cys-LT generation, and whether it may be critical for Dectin-2 signaling more broadly.

In this study, we find that *D. farinae* stimulation of BMDCs elicits phosphorylation of Akt, a PI3K-dependent kinase, and inhibition of PI3K reduces *D. farinae*-elicited cys-LTs, IL-23, and IL-33, suggesting that PI3K activity regulates Dectin-2 signaling. PI3K δ is the most abundant class I PI3K isoform in BMDCs, and both pharmacologic inhibition and small interfering RNA (siRNA) knockdown of PI3K δ reduce *D. farinae*-elicited cys-LTs, IL-23, and IL-33. Inhibition of PI3K δ also reduces cys-LTs and cytokines elicited by Dectin-2 cross-linking, demonstrating that PI3K δ is an important signaling intermediate in the Dectin-2 pathway. Whereas *D. farinae*-elicited PI3K δ activity and the generation of each inflammatory mediator depends on Syk, inhibition of PI3K δ has no effect on Syk phosphorylation but reduces the phosphorylation of PKC δ , indicating that PI3K δ is a proximal Syk-dependent signaling intermediate. Inhibition of PI3K δ potently reduces DC-mediated sensitization, as wild-type (WT) mice sensitized with PI3K δ -treated *D. farinae*-pulsed BMDCs have a dramatic attenuation in allergic pulmonary inflammation and Th2/Th17 cytokine production after *D. farinae* challenge. Furthermore, selective treatment of WT mice with a PI3K δ inhibitor during sensitization attenuates the generation of *D. farinae*-induced pulmonary inflammation. These findings demonstrate that PI3K δ regulates divergent Dectin-2-dependent signaling pathways to promote both Th2 and Th17 immunity. Thus, strategies to inhibit the mucosal activation of PI3K δ may have therapeutic efficacy in allergen-induced pulmonary inflammation.

Materials and Methods

Mice

C57BL/6 WT mice were purchased from Charles River Laboratories and ROSA26-enhanced GFP (EGFP) transgenic mice [Tg(Gt(ROSA)26Sor-EGFP)11Able] were purchased from The Jackson Laboratory. *Ltc4s*^{-/-} mice were generated and maintained in our laboratory (25). *Clec4e*^{-/-} mice (2) and *Card9*^{-/-} mice (26) were generated as previously described. IL-33-deficient (*Il33*^{-/-}) mice were provided by Pfizer Research (Cambridge, MA). All mice were on C57BL/6 background and were 8–12 wk old for in vivo experiments. All animal studies were approved and in accordance of the Animal Care and Use Committee of the Dana-Farber Cancer Institute.

Reagents

D. farinae extracts (Greer Laboratories, Lenoir, NC) were reconstituted in PBS. LPS from *Escherichia coli* 055:B5 was obtained from Sigma-Aldrich (St. Louis, MO). Curdlan (Wako Pure Chemical Industries, Osaka, Japan) was dissolved in DMSO. Rat anti-mouse Dectin-2 IgG2a (clone D2.11E4; AbD Serotec, Raleigh, NC) and goat anti-rat IgG2a (Jackson ImmunoResearch Laboratories, West Grove, PA) were used for Dectin-2 cross-linking. Pan-PI3K inhibitor (Ly294002; EMD Millipore, Billerica, MA), PI3K p110 δ inhibitors (CAL-101 and IC87114; Selleckchem, Houston, TX), PI3K p110 β inhibitor (TGX-221; Selleckchem), Syk inhibitor II (Santa Cruz Biotechnology, Dallas, TX), and Syk inhibitor (R406; Selleckchem) were dissolved in DMSO.

BMDC generation and Dectin-2 activation

BMDCs were generated with GM-CSF according to Lutz et al. (27) and as previously described (28). Briefly, bone marrow was harvested from the

femur, washed, and plated in petri dishes at 4×10^5 cells/ml in complete media consisting of RPMI 1640 with 10% heat-inactivated FCS, 100 U/ml penicillin, 100 μ g/ml streptomycin, 2 mM L-glutamine, 5 μ M 2-ME, and 40 ng/ml recombinant mouse GM-CSF (PeproTech, Rocky Hill, NJ). This suspension was cultured at 37°C in a 5% CO₂ incubator. On day 3, 10 ml complete media was added. On day 6, 10 ml complete media was exchanged. Harvested cells on day 7 were washed and counted for stimulation. Cells were plated at 1×10^6 cells/ml and stimulated with *D. farinae* for the indicated times.

Dectin-2 cross-linking assay

Tissue culture plates were incubated with goat F(ab')₂ anti-rat IgG2a at 4°C overnight. The next day, the plates were washed with PBS and incubated with rat anti-mouse Dectin-2 IgG2a dissolved in PBS with 1% BSA at indicated doses for 2 h. The plate was washed again with PBS, and BMDCs ($2.5\text{--}5 \times 10^5$ cells) were added and incubated in 37°C in a 5% CO₂ incubator for indicated times. Supernatants and cell lysates were collected for cytokine analysis.

Cys-LT and cytokine measurements

Cys-LTs in the cultured supernatants at 30 min were analyzed by ELISA according to the manufacturer's protocol (Cayman Chemical, Ann Arbor, MI). IL-23 and TNF- α in the cultured supernatants and IL-33 in the cell lysates after freeze and thaw were measured by ELISA (eBioscience, San Diego, CA) at an 8 h time point, unless otherwise indicated. Lymph node cells were cultured at 4×10^6 cells/ml, stimulated with 20 μ g/ml *D. farinae* for 72 h, and IL-4, IL-5, IL-13, IL-17A, and IFN- γ were measured by ELISA (eBioscience) in the cultured supernatants.

Quantitative PCR

RNA was extracted from BMDCs with TRIzol reagent, and cDNA was generated using a first-strand kit (Thermo Scientific, Waltham, MA). Transcripts were measured using Mx3006P real-time PCR systems (Agilent Technologies, Santa Clara, CA) with PI3K β , PI3K δ , IL-23, IL-33, 18S, and GAPDH primers (SABiosciences, Frederick, MD).

Western blot

After treatment with or without *D. farinae* in the presence or absence of PI3K inhibitor for the indicated times, the cells were lysed in Nonidet P-40 lysis buffer (Boston BioProducts, Ashland, MA). The total cellular protein concentrations were then quantified using a bicinchoninic acid assay (Pierce, Rockford, IL, USA). After quantification, 10 μ g denatured protein was loaded onto 10 or 12% SDS-PAGE gels (Bio-Rad Laboratories, Hercules, CA). The protein was then transferred to a polyvinylidene difluoride membrane (Bio-Rad Laboratories) and blocked in TBS-T containing BSA or nonfat milk (1 \times TBS, 5% BSA or nonfat milk, 0.05% Tween 20) depending on the primary Ab for 60 min. The blocked membranes were then incubated overnight at 4°C with Abs to phosphorylated Akt Ser⁴⁷³, phosphorylated Syk Tyr^{525/526}, phosphorylated PKC δ Tyr³¹¹ (1:1000 dilution; Cell Signaling Technology, Beverly, MA) or PI3K δ (1:500 dilution; Santa Cruz Biotechnology). The following day, membranes were washed three times with TBS-T wash buffer (1 \times TBS, 0.05% Tween 20). Membranes were incubated for 60 min with HRP-conjugated anti-rabbit secondary Ab (Santa Cruz Biotechnology; 1:10,000 dilution) and washed three times in TBS-T wash buffer. The membrane was developed using SuperSignal West Femo (Thermo Scientific). For total Akt, the same membranes were stripped with Restore Plus Western blot stripping buffer reagent (Thermo Scientific) according to the manufacturer's instructions, followed by TBS wash and blocked in TBS-T containing nonfat milk (1 \times PBS, 5% nonfat milk, 0.05% Tween 20) for 60 min. The blocked membrane was then incubated at 4°C overnight with Akt or GAPDH (1:1000–1:5000 dilution; Cell Signaling Technology) Ab for subsequent analysis.

PI3K δ siRNA knockdown

Day 7 WT BMDCs were transfected with PI3K δ or nontargeting control siRNA (GE Dharmacon, Lafayette, CO) using an Amaxa DC transfection kit reagent (Invitrogen) according to the manufacturer's protocol. After transfection, BMDCs were stimulated with 200 μ g/ml *D. farinae* or 100 ng/ml LPS for 30 min for cys-LTs and 6 h for cytokines and analyzed by quantitative PCR or ELISA.

Adoptive transfer protocol

Day 7 BMDCs were stimulated with PBS or *D. farinae* in the presence or absence of CAL-101 at the concentration of 10 nM for 8 h and washed twice and resuspended in PBS. WT mice were sensitized with 10^4 cells in 20 μ l PBS intranasally on day 0, challenged with 3 μ g *D. farinae* on days

11 and 13, and killed on day 15 with pentobarbital overdose. Bronchoalveolar lavage (BAL) fluid and mediastinal lymph node (MDLN) cells were collected for analysis. For adoptive transfer of BMDCs from transgenic GFP mice, 1×10^6 cells in 20 μ l PBS were administered intranasally into WT recipients, and MDLN cells were collected the following day for analysis.

Flow cytometry

For live cell/dead cell discrimination, Zombie Aqua dye (BD Biosciences, San Jose, CA) was used according to the manufacturer's protocol. Isolated MDLN cells were first blocked with 1% mouse IgG (Sigma-Aldrich) and 1% anti-mouse CD16/CD32 (BD Biosciences), then stained with anti-mouse MHC class II–Alexa Fluor 627 (clone M5/114.15.2; BD Biosciences) and anti-mouse CD11c–allophycocyanin-Cy7 (clone N418; BD Biosciences), according to the manufacturer's protocol. Analyses were performed on a FACSCanto flow cytometer (BD Biosciences), and data were analyzed with FlowJo 7.5.

Direct sensitization and challenge protocol

On day 0, WT mice were sensitized with 3 μ g *D. farinae* intranasally. PI3K δ inhibitor IC87114 (30 mg/kg) (29, 30) or vehicle control (PEG-400) was administered orogastrically at 1 h before and 8 h after *D. farinae* administration. Mice were then challenged intranasally with 3 μ g *D. farinae* on days 11 and 13 and killed on day 15. BAL fluid was collected as described below.

BAL and lymph node isolation

BAL fluid was collected via three instillations of 0.75 ml PBS plus 1 mM EDTA, and cells were pelleted for counting (14). Cells (4×10^5) in 200 μ l were centrifuged and counted after staining with Hema 3 Stain Set (Thermo Scientific). A total of 200 cells per slide were counted and discriminated based on morphological differences. Isolated mediastinal lymph node cells were filtered through 70- μ m strainers, washed, and plated at 4×10^6 cells/ml. Cells were restimulated with *D. farinae* at 20 μ g/ml for 72 h and supernatants were collected for cytokine analysis.

Histology

The left lung was removed and fixed in 4% paraformaldehyde solution. Histology sections were prepared as previously described (28). They were stained with H&E for general morphology and periodic acid–Schiff for mucus and goblet cell identification.

Statistical analysis

Results were expressed as means \pm SEM. Unpaired Student *t* tests were used for the statistical analysis unless stated otherwise. To compare between multiple genotypes or stimuli, one-way ANOVA tests were used. To compare multiple genotypes over doses or time, two-way ANOVA tests were used with Bonferroni posttests. A *p* value <0.05 was considered significant.

Results

HDM stimulation elicits PI3K activity and the generation of cys-LTs, IL-23, and IL-33 in a PI3K-dependent manner

To determine whether PI3K plays a central role in Dectin-2 signaling, we first assessed BMDC activation in response to *D. farinae*. Phosphorylation of Akt, a PI3K-dependent serine-threonine kinase, was detected in WT BMDCs stimulated with *D. farinae* at 1 min (Fig. 1A). This induction was absent in *D. farinae*–stimulated BMDCs treated with the pan-PI3K inhibitor Ly294002. To determine whether PI3K activity was required for the production of each Dectin-2–dependent inflammatory mediator, we stimulated WT BMDCs with *D. farinae* in the presence of Ly294002. *D. farinae* elicited cys-LTs at 30 min, and IL-23 and IL-33 at 8 h in a dose-dependent manner, which was absent in *Clec4n*^{−/−} BMDCs (Fig. 1B–D). The specificity of IL-33 protein measurement was verified by the absence of detection in *D. farinae*–stimulated *Il33*^{−/−} BMDCs (data not shown). PI3K inhibition reduced production of *D. farinae*–induced cys-LTs, IL-23, and IL-33 with IC₅₀ values of 0.7, 0.9, and 0.5 μ M, respectively (Fig. 1E–G). PI3K inhibition had no effect on LPS-induced TNF- α generation (Fig. 1H), demonstrating the specificity of PI3K inhibition.

D. farinae elicits cys-LTs through Dectin-2, the ITAM-bearing FcR γ -chain, and the downstream activation of Syk. To determine whether PI3K activity depends on Syk, we assessed the phosphorylation of Akt in the presence of the Syk inhibitor R406. *D. farinae* stimulation of WT BMDCs triggered phosphorylation of Akt at 1 min (Fig. 2A), which was reduced by $88 \pm 2\%$ in the presence of R406. In keeping with the role of Syk as an upstream mediator of the Dectin-2 pathway, blockade of Syk with two different inhibitors, Syk II and R406, significantly reduced the production of *D. farinae*–elicited cys-LTs, IL-23, and IL-33 in a dose-dependent manner (Fig. 2B–G). LPS-induced TNF- α generation was intact in the presence of each Syk inhibitor, indicating the specificity of inhibition (Fig. 2H). These findings demonstrate that both PI3K and Syk are required for production of each Dectin-2–dependent mediator in response to *D. farinae* and that PI3K activity depends on Syk.

PI3K p110 δ isoform regulates Dectin-2 signaling

Next we investigated which isoform of PI3K is required for Dectin-2 signaling elicited by *D. farinae*. WT BMDCs expressed each class I PI3K isoform, with PI3K δ being the most abundant (Fig. 3A). There was no difference in PI3K isoform expression between WT and *Clec4n*^{−/−} BMDCs. Two isoforms of class I PI3K, p110 β (PI3K β) and p110 δ (PI3K δ), have been linked to the function of FcR γ -chain–dependent receptors in myeloid cells (24, 31). To assess their role in Dectin-2 signaling, we first used available inhibitors. Inhibition of PI3K δ with CAL-101 reduced *D. farinae*–induced cys-LTs, IL-23, and IL-33 with IC₅₀ values of 0.5, 1.63, and 1.67 nM, respectively (Fig. 3B–D). The inhibition was specific, as BMDCs treated with higher levels of inhibitor had no reduction in LPS-induced TNF- α (Fig. 3E). Similarly, use of another highly specific PI3K δ inhibitor, IC87114, also significantly reduced *D. farinae*–induced cys-LTs, IL-23, and IL-33 (Fig. 3F–H), with intact LPS-induced TNF- α (Fig. 3I). In contrast, treatment with a PI3K β inhibitor at doses specific for the p110 β isoform had no effect on the levels of *D. farinae*–induced cys-LTs, IL-23, or IL-33 and no effect on LPS-induced TNF- α (Supplemental Fig. 1). At 100 nM PI3K β inhibitor, a dose previously reported to also block PI3K δ (32), there was a small trend to reduced cys-LTs and IL-33 that was not significant.

In keeping with our prior data suggesting that PI3K activity is downstream of Syk (Fig. 2A), PI3K δ inhibition had no effect on Syk phosphorylation (Fig. 3J). PKC δ , another downstream Syk-dependent signaling molecule in the Dectin-2 pathway, phosphorylates CARD9 to facilitate NF- κ B activation and the generation of Dectin-2–dependent cytokines elicited by *C. albicans* (2, 6). To determine whether PI3K δ is upstream of PKC δ and CARD9 activation, we assessed the effect of PI3K δ inhibition on *D. farinae*–elicited PKC δ phosphorylation. *D. farinae* stimulation of WT BMDCs induced phosphorylation of PKC δ , which was detected at 5 and 15 min (Fig. 3K). PI3K δ inhibition reduced PKC δ phosphorylation by $90 \pm 3\%$ at 15 min, indicating that PI3K δ is proximal to PKC δ and CARD9 signaling. In keeping with a downstream role for CARD9 in *D. farinae*–elicited signaling, we did find that *D. farinae*–stimulated *Card9*^{−/−} BMDCs had reduced generation of both IL-23 and IL-33, but preserved cys-LT generation (Supplemental Fig. 2).

To confirm a requirement for PI3K δ in Dectin-2 signaling, we used a knockdown approach. WT BMDCs were harvested on day 7, treated with PI3K δ siRNA or nontargeting siRNA control (control siRNA) by nucleofection, and stimulated with *D. farinae* 24 h later. At 24 h, PI3K δ siRNA–treated BMDCs had a significant reduction in PI3K δ transcript (Fig. 4A), but no reduction in transcript for PI3K α , β , or γ isoforms (Fig. 4B–D). Western blotting confirmed a reduction in PI3K δ protein in siRNA–treated




FIGURE 1. PI3K activity is required for the generation of each Dectin-2 mediator. **(A)** Representative Western blot from one of two independent experiments. Phosphorylation of Akt in WT BMDCs stimulated with 0 (–) or 100 μg/ml *D. farinae* (+) for 1 min in the presence of 3 μM Ly294002 (pan-PI3K inhibitor) or vehicle control. **(B–D)** Day 7 BMDCs from WT and *Clec4n*^{-/-} mice were stimulated with increasing doses of *D. farinae*. Cys-LTs and IL-23 were measured in supernatants and IL-33 in the cell lysates by ELISA at 30 min, 8 h, and 8 h, respectively. $p = 0.0004$ for cys-LTs, $p < 0.0001$ for IL-23 and IL-33. **(E–H)** WT BMDCs were stimulated with PBS or (E–G) 100 μg/ml *D. farinae* or (H) 100 ng/ml LPS in the presence of Ly294002 at indicated doses. $p < 0.01$ for cys-LTs and IL-23, $p < 0.05$ for IL-33, and not significant for TNF-α. Results are means ± SEM pooled from three independent experiments. Significance was determined with two-way ANOVA. Df, *D. farinae*.

BMDCs relative to controls (Fig. 4E), and the reduction averaged $64 \pm 4\%$ at 24 h (Fig. 4F). Accordingly, *D. farinae*-induced cys-LTs, IL-23, and IL-33 were significantly reduced (Fig. 4G–I), as compared with control siRNA-treated BMDCs. The inhibition was specific, as PI3Kδ siRNA-treated BMDCs had no reduction in LPS-elicited TNF-α (Fig. 4J). These results demonstrate that PI3Kδ mediates *D. farinae*-elicited Dectin-2 signaling.

To verify that PI3Kδ activity contributes specifically to Dectin-2 signaling, BMDCs were activated with plate-bound Dectin-2 Ab

overnight in the presence of 0, 10, or 100 nM PI3Kδ inhibitor. Dectin-2 cross-linking elicited cys-LTs and IL-33, each of which was absent in *Clec4n*^{-/-} BMDCs (Fig. 5A, 5B). IL-23 was also detected, but high levels were elicited from plate-bound IgG controls (data not shown). TNF-α, another Dectin-2- and CARD9-dependent cytokine, was also elicited by Dectin-2 cross-linking and significantly reduced in *Clec4n*^{-/-} BMDCs (Fig. 5C). Treatment with a PI3Kδ inhibitor reduced Dectin-2-elicited cys-LTs, IL-33, and TNF-α in a dose-dependent fashion (Fig. 5). These results




FIGURE 2. *D. farinae*-elicited PI3K activity, cys-LTs, and cytokines depend on Syk. **(A)** Phosphorylation of Akt in WT BMDCs stimulated with 100 μ g/ml *D. farinae* (+) at various time points in the presence of 300 nM R406 (Syk inhibitor) or vehicle control. **(B–G)** WT BMDCs were stimulated with PBS or 100 μ g/ml *D. farinae* or **(H)** 100 ng/ml LPS in the presence of specific Syk inhibitors, **(B–D)** Syk II inhibitor, $p < 0.0001$ for cys-LTs, $p < 0.05$ for IL-23 and IL-33, or **(E–G)** R406, $p < 0.05$ for cys-LTs, IL-23, and IL-33. Results are means \pm SEM pooled from three independent experiments. Significance was determined with one-way ANOVA. Df, *D. farinae*.

further demonstrate that PI3K δ is an essential component of Dectin-2 signaling and mediates the generation of both cys-LTs and cytokines.

PI3K δ is required for Dectin-2-mediated pulmonary inflammation in vivo

To understand whether PI3K δ activity is essential for *D. farinae*-induced pulmonary inflammation, we used an adoptive transfer model in mice (14). WT BMDCs were pulsed with either PBS (PBS-DCs) or *D. farinae* in the presence of the PI3K δ inhibitor CAL-101 (PI3K δ -*D. farinae*-DCs) or vehicle control (*D. farinae*-DCs) for 8 h, washed, and transferred intranasally into naive WT C57BL/6 recipient mice on day 0. All recipients were challenged intranasally with 3 μ g *D. farinae* on days 11 and 13, and killed on day 15. WT mice sensitized with *D. farinae*-DCs showed

inflammation in the BAL fluid after *D. farinae* challenge, as compared with mice sensitized with PBS-DCs (Fig. 6A). This included an influx of macrophages, neutrophils, and eosinophils. Mice sensitized with PI3K δ -*D. farinae*-DCs had significant and marked reductions in total cell counts of 80%, neutrophils of 91%, and eosinophils of 96%, as compared with mice sensitized with vehicle control-treated *D. farinae*-DCs.

PI3K δ treatment of BMDCs did not influence BMDC survival, as PI3K δ -*D. farinae*-DCs cultured for an additional 48 h demonstrated no difference in staining with a nonpermeant amine-reactive fluorescent viability dye compared with vehicle control-treated *D. farinae*-DCs (Supplemental Fig. 3A). Furthermore, EGFP⁺ PI3K δ -*D. farinae*-DCs were detected in the MDLNs of recipient mice at 24 h after adoptive transfer in comparable numbers to EGFP⁺ vehicle control-treated *D. farinae*-DCs (Supplemental Fig. 3B).




FIGURE 3. Pharmacologic inhibition suggests that PI3Kδ is required for cys-LTs, cytokines, and activation of PKCδ. **(A)** PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ transcript expression relative to GAPDH in WT and *Clec4n^{-/-}* BMDCs. **(B–E)** WT BMDCs were stimulated with PBS or 100 μg/ml *D. farinae* or 100 ng/ml LPS in the presence of **(B–E)** CAL-101 or **(F–I)** IC87114. For CAL-101, $p < 0.001$ for cys-LTs and for IL-23, $p < 0.0001$ for IL-33. For IC87114, $p < 0.05$ for cys-LTs, IL-23, and IL-33. Results are means \pm SEM pooled from three independent experiments. Significance was determined with one-way ANOVA. **(J)** Phosphorylation of Syk in WT BMDCs stimulated with 100 μg/ml *D. farinae* at various time points in the presence of 100 nM CAL-101 (PI3Kδ inh) or vehicle control (Veh Ctrl). **(K)** Phosphorylation of PKCδ in WT BMDCs stimulated with 100 μg/ml *D. farinae* at various time points in the presence of 100 nM CAL-101 or vehicle control. Representative Western blot from one of two independent experiments (J and K).


Histologic analysis of the lung stained with H&E showed that mice sensitized with *D. farinae*-DCs had dense cellular infiltrates around the bronchovascular bundles that were not present in mice sensitized with PBS-DCs (Fig. 6B, H&E). These infiltrates were markedly diminished in mice sensitized with PI3Kδ-*D. farinae*-DCs. Goblet cell metaplasia and mucus production, as detected by periodic acid-Schiff (PAS) staining, were also present in mice sensitized with *D. farinae*-DCs, but were absent in mice sensitized with either PBS-DCs or PI3Kδ-*D. farinae*-DCs (Fig. 6B, PAS). Thus, PI3Kδ is critical for the capacity of BMDCs to elicit *D. farinae*-induced pulmonary inflammation.

To understand whether PI3Kδ-*D. farinae*-DCs elicited an altered T cell cytokine response, we harvested the MDLN cells from each cohort at day 15, restimulated them with 20 μg/ml *D. farinae* for 72 h, and assayed for T cell cytokines in cultured supernatants (14, 33). MDLN cell cultures from WT mice sensitized with *D. farinae*-DCs generated high levels of IL-4, IL-5, IL-13, and IL-17A, as compared with those sensitized with PBS-DCs (Fig. 6C).

MDLN cell cultures from WT mice sensitized with PI3Kδ-*D. farinae*-DCs generated significantly less IL-4, IL-5, IL-13, and IL-17A. MDLN cell cultures from each group generated high levels of IFN-γ, consistent with an Ag-independent response to DC adoptive transfer previously reported (14). Thus, PI3Kδ is critical for the capacity of BMDCs to generate pulmonary inflammation and Th2 and Th17 immunity to *D. farinae*.

To verify that PI3Kδ was important in priming through the mucosal route, we treated WT mice with 3 μg intranasal *D. farinae* on days 0, 10, and 12, and with the PI3Kδ inhibitor IC87114 or vehicle control by oral gavage on day 0. IC87114 was chosen based on its established use in murine models of inflammation (29, 30, 34). The BAL fluid at day 14 revealed pulmonary inflammation in WT mice sensitized and challenged with *D. farinae* that included both eosinophils and neutrophils (Fig. 6D). Mice treated with the PI3Kδ inhibitor on day 0 showed attenuated development of *D. farinae*-elicited pulmonary inflammation with significant reductions in total BAL fluid cell counts, macrophages, neutrophils,

FIGURE 4. PI3K δ knockdown confirms a role for PI3K δ in Dectin-2 signaling. Day 7 WT BMDCs were transfected with nontargeting control siRNA or PI3K δ siRNA. (A–D) PI3K δ , PI3K α , PI3K β , and PI3K γ transcript expression relative to 18S in nontargeting control siRNA or PI3K δ siRNA group. (E) Representative Western blots of PI3K δ and GAPDH in BMDCs transfected with either nontargeting control siRNA or PI3K δ siRNA. (F) Densitometric analysis of PI3K δ proteins relative to GAPDH on Western blots in control (set as 1) and PI3K δ siRNA transfected groups. (G–I) *D. farinae*-elicited cys-LTs at 30 min, and IL-23 and IL-33 expression at 6 h, as compared with control siRNA-treated BMDCs. (J) LPS-elicited TNF- α at 6 h, as measured by ELISA. Results are means \pm SEM pooled from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.0001 compared with control siRNA.



and eosinophils, as compared with mice treated with vehicle control. These results further suggest that PI3K δ plays an important role in the generation of *D. farinae*-elicited allergic pulmonary inflammation.

Discussion

Our study demonstrates that PI3K δ is an important signaling intermediate in the DC Dectin-2 signaling pathway elicited either by *D. farinae* or by Ab-mediated cross-linking. We found that PI3K δ is Syk-dependent and regulates PKC δ activation and the generation of both cys-LTs and cytokines elicited by *D. farinae*. Accordingly, two models of *D. farinae*-elicited Dectin-2-dependent allergic pulmonary inflammation were significantly attenuated by PI3K δ inhibition, indicating the importance of Dectin-2 and PI3K δ in the immune response triggered by this common allergen.

To our knowledge, this is the first study to identify PI3K δ in CLR signaling. However, because several members of the myeloid CLR family use a shared Syk signaling pathway (1), PI3K δ may

regulate the signaling of additional receptors. Indeed, we have found that the Dectin-1 agonist, curdlan, also induces cys-LTs in a manner that partially depends on PI3K δ (data not shown). As PI3K δ inhibitors are in clinical trials for B cell malignancies, further identifying such roles will be important to understand the possible risks associated with systemic PI3K δ inhibition.

PI3K δ is an upstream mediator of several membrane-bound receptors that use ITAM/Syk-dependent signaling, including the BCR and the TCR (22). Ligation of the BCR causes tyrosine kinase-mediated phosphorylation of Ig α and Ig β , and recruitment of PI3K through phosphorylation of the YXXM-bearing CD19 coreceptor and the B cell adaptor for PI3K (35, 36). TCR activation of PI3K also depends on tyrosine kinase signaling and has been variably attributed to the YXXM-bearing adaptor protein TCR interacting molecule (37) or to phosphorylation of additional non-ITAM tyrosine-containing proteins such as the linker of activated T cells and Src homology 2 domain-containing leukocyte protein of 76 kDa (38, 39). Our finding that *D. farinae*-elicited PI3K activity




FIGURE 5. PI3K δ inhibition reduces Dectin-2 signaling elicited by Ab-mediated cross-linking. WT and *Clec4n*^{-/-} BMDCs were stimulated with plate-bound Dectin-2 Ab overnight in the presence or absence of CAL-101. (A–C) The concentrations of cys-LTs and TNF- α in the supernatants and of IL-33 in the cell lysates were measured by ELISA. Results are means \pm SEM pooled from three independent experiments. p < 0.001 (cys-LTs), p < 0.01 (TNF- α), p < 0.05 (IL-33). Significance was determined with one-way ANOVA.




FIGURE 6. PI3K δ is required for Dectin-2-mediated pulmonary inflammation in vivo. (**A–C**) WT mice were sensitized with 10^4 PBS- or *D. farinae*-pulsed BMDCs in the presence or absence of PI3K δ inhibitor CAL-101 at 10 nM (PBS-DCs, *D. farinae*-DCs, PI3K δ -*D. farinae*-DCs), challenged with 3 μ g *D. farinae* on days 11 and 13 and killed on day 15. (**A**) Total and differential cell counts for BAL fluid macrophages, neutrophils, eosinophils, and lymphocytes. (**B**) H&E and PAS staining of lung tissue from each group. (**C**) MDLN cells were isolated and restimulated with 20 μ g/ml *D. farinae* for 72 h. Cytokines were measured in the supernatants. Results are means \pm SEM ($n = 8, 13$, and 15 mice for PBS-DC, *D. farinae*-DC, PI3K δ -*D. farinae*-DC groups, respectively) from three experiments. (**D**) On day 0, WT mice were sensitized with 3 μ g *D. farinae* intranasally. PI3K δ inhibitor IC87114 (30 mg/kg) or vehicle control (PEG-400) was administered orogastrically at 1 h before and 8 h after *D. farinae* administration. Mice were then challenged intranasally with 3 μ g *D. farinae* on days 11 and 13 and killed on day 15. Total and differential cell counts for BAL fluid macrophages, neutrophils, eosinophils, and lymphocytes are shown. Results are means \pm SEM ($n = 8$ and 10 mice for *D. farinae*-vehicle- and *D. farinae*-PI3K δ -treated groups, respectively) pooled from three independent experiments. * $p < 0.05$, ** $p < 0.01$. *Df*, *D. farinae*.

depends on Syk is in keeping with these studies. However, neither Dectin-2, Fc γ R, nor Dectin-3, which dimerizes with Dectin-2 (40), contains the tyrosine motifs that support PI3K δ recruitment. As such, our study suggests that Dectin-2 uses additional adaptor proteins as the docking site for the Src homology 2 domain-containing p85 regulatory subunit of PI3K δ . Notably, the tyrosine-containing adaptor protein linker for activation of B cells/non-T cell activating linker was recently reported to be phosphorylated after Dectin-2 activation (41), but whether Dectin-2 utilizes

this protein or an as yet unidentified YXXM-bearing adaptor protein to support PI3K δ activation remains to be determined.

The generation of cys-LTs is unique to CLRs among pattern recognition receptor families, likely due to the sustained calcium flux that is required to translocate cytosolic phospholipase A₂ from the cytosol to the nuclear membrane to release arachidonate from membrane phospholipids (10, 42). PI3K plays a key role in mobilizing calcium and activating PKCs in response to Fc ϵ R1 signaling or BCR signaling by activating PLC γ (24, 43, 44). Recent studies

on Dectin-1 and Dectin-2 have also demonstrated that PLC γ is required for eliciting a calcium flux and for PKC δ - and CARD9-dependent cytokine generation (6, 45, 46). Moreover, our data demonstrate that inhibition of PI3K δ impairs PKC δ phosphorylation elicited by *D. farinae*. Taken together, these studies indicate that PI3K δ is a proximal mediator of Dectin-2–dependent arachidonate metabolism and cytokine generation and likely acts by triggering activation of PLC γ .

We found that Dectin-2, PI3K δ , and CARD9 were required for *D. farinae*-elicited IL-33 generation in DCs. IL-33 generation in APCs can be induced by multiple stimuli such as influenza virus (18), *Nippostrongylus brasiliensis* (47), *Histoplasma capsulatum* (48), and TLR agonists (49), and prior studies have demonstrated roles for both IFN regulatory factors (IRFs) and NF- κ B in the transcriptional regulation of IL-33. IRF3 is required for TLR3 and TLR4-induced IL-33 in murine macrophages (49), and IRF4 is required for both Dectin-1- and Dectin-2-induced IL-33 in macrophages and DCs, respectively (48, 50). However, NF- κ B is required for TLR5-induced IL-33 generation from murine DCs (51) and for TLR3- and TLR5-induced IL-33 from human epithelial cells (52). In keeping with these findings, our results show that *D. farinae*-induced IL-33 generation is reduced in *Card9*^{−/−} BMDCs but more significantly attenuated with PI3K δ inhibition, suggesting that PI3K δ signaling can promote IL-33 induction through both CARD9-dependent NF- κ B activation and CARD9-independent IRF4 activation.

We and others have identified a role for Dectin-2 in the generation of both Th2- and Th17-dependent allergic pulmonary inflammation to HDM (14, 15, 19, 50). In the present study, we demonstrate that PI3K δ signaling in DCs is required for this function, as the adoptive transfer of PI3K δ -inhibited *D. farinae*-DCs had a reduced capacity to generate Th2- and Th17-dependent allergic pulmonary inflammation. We have previously demonstrated a role for the Dectin-2/LTC₄S pathway in the type 1 cys-LT receptor-dependent conditioning of DCs to promote Th2 sensitization (14), but our findings in the present study suggest that an additional Dectin-2 mediator, IL-33, may participate in this process. IL-33 promotes Th2 immunity through several actions, including the upregulation of DC costimulatory molecules and the polarization of naive T cells to Th2 (18). Although IL-33 is widely expressed (18), it is bound and neutralized by circulating soluble ST2 (18), suggesting that anatomic and temporal control of IL-33 generation may regulate its function and that the DC-specific generation of IL-33 in response to allergen may contribute to local polarization in the lymph node.

We found that inhibition of PI3K δ solely on the day of *D. farinae* sensitization prevented allergic pulmonary inflammation elicited by *D. farinae* challenge 2 wk later. Because of the short *t*_{1/2} of the PI3K δ inhibitor used (53), the results of PI3K δ inhibition *in vivo* are likely due to proximal effects on DC-mediated sensitization, which occurs during the first 24–72 h (54), but additional effects on the activation of T cells or B cells cannot be excluded. Several previous studies have demonstrated a role for PI3K δ in the effector phase of Ag-induced allergic pulmonary inflammation. In these studies, the airway administration of a PI3K δ inhibitor during the OVA challenge of previously sensitized mice reduced BAL eosinophilia, Th2 and Th17 lung cytokine production, airway hyper-responsiveness, and OVA-specific IgE (29, 34). Furthermore, PI3K δ ^{D910A/D910A} mice, which express a catalytically inactive form of PI3K δ , were also protected from BAL eosinophilia and Th2 cytokine production in models of Th2 pulmonary inflammation using sensitization and challenge to OVA (55) or to uric acid (56). Although the present study demonstrates a key role for PI3K δ in DC function during the sensitization phase, the same Dectin-2 pathway contributes

to pulmonary inflammation in effector phase responses (33). Thus, use of a well-tolerated and highly specific PI3K δ inhibitor such as CAL-101 (also known as idelalisib), with recently reported efficacy in lymphoma (57), may be a rational therapeutic strategy to prevent the mucosal activation of both lymphoid and myeloid cells that participate in type 2 pulmonary inflammation.

Acknowledgments

We thank K. Frank Austen for critical reading of the manuscript, Karl Nocka and Peter Symanowicz for providing reagents, and Li Li and Juying Lai for technical assistance.

Disclosures

The authors have no financial conflicts of interest.

References

- Sancho, D., and C. Reis e Sousa. 2012. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. *Annu. Rev. Immunol.* 30: 491–529.
- Saijo, S., S. Ikeda, K. Yamabe, S. Kakuta, H. Ishigame, A. Akitsu, N. Fujikado, T. Kusaka, S. Kubo, S. H. Chung, et al. 2010. Dectin-2 recognition of α -mannans and induction of Th17 cell differentiation is essential for host defense against *Candida albicans*. *Immunity* 32: 681–691.
- Robinson, M. J., F. Osorio, M. Rosas, R. P. Freitas, E. Schweighoffer, O. Gross, J. S. Verbeek, J. Ruland, V. Tybulewicz, G. D. Brown, et al. 2009. Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. *J. Exp. Med.* 206: 2037–2051.
- Deng, Z., S. Ma, H. Zhou, A. Zang, Y. Fang, T. Li, H. Shi, M. Liu, M. Du, P. R. Taylor, et al. 2015. Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal Th17 responses. *Nat. Immunol.* 16: 642–652.
- Sato, K., X. L. Yang, T. Yudate, J. S. Chung, J. Wu, K. Luby-Phelps, R. P. Kimberly, D. Underhill, P. D. Cruz, Jr., and K. Ariizumi. 2006. Dectin-2 is a pattern recognition receptor for fungi that couples with the Fc receptor γ chain to induce innate immune responses. *J. Biol. Chem.* 281: 38854–38866.
- Strasser, D., K. Neumann, H. Bergmann, M. J. Marakalala, R. Guler, A. Rojowska, K. P. Hopfner, F. Brombacher, H. Urlaub, G. Baier, et al. 2012. Syk kinase-coupled C-type lectin receptors engage protein kinase C- σ to elicit Card9 adaptor-mediated innate immunity. *Immunity* 36: 32–42.
- Bi, L., S. Gojestani, W. Wu, Y. M. Hsu, J. Zhu, K. Ariizumi, and X. Lin. 2010. CARD9 mediates Dectin-2-induced I κ B α kinase ubiquitination leading to activation of NF- κ B in response to stimulation by the hyphal form of *Candida albicans*. *J. Biol. Chem.* 285: 25969–25977.
- Gringhuis, S. I., B. A. Wevers, T. M. Kaptein, T. M. M. van Capel, B. Theelen, T. Boekhout, E. C. de Jong, and T. B. H. Geijtenbeek. 2011. Selective C-Rel activation via Malt1 controls anti-fungal Th17 immunity by dectin-1 and dectin-2. *PLoS Pathog.* 7: e1001259.
- Brock, T. G., R. W. McNish, and M. Peters-Golden. 1995. Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages. *J. Biol. Chem.* 270: 21652–21658.
- Clark, J. D., L. Lin, R. W. Kriz, C. S. Ramesha, L. A. Sultzman, A. Y. Lin, N. Milona, and J. L. Knopf. 1991. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca²⁺-dependent translocation domain with homology to PKC and GAP. *Cell* 65: 1043–1051.
- Lam, B. K., J. F. Penrose, G. J. Freeman, and K. F. Austen. 1994. Expression cloning of a cDNA for human leukotriene C₄ synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A₄. *Proc. Natl. Acad. Sci. USA* 91: 7663–7667.
- Barrett, N. A., A. Maekawa, O. M. Rahman, K. F. Austen, and Y. Kanaoka. 2009. Dectin-2 recognition of house dust mite triggers cysteinyl leukotriene generation by dendritic cells. *J. Immunol.* 182: 1119–1128.
- Suram, S., T. A. Gangelhoff, P. R. Taylor, M. Rosas, G. D. Brown, J. V. Bonventre, S. Akira, S. Uematsu, D. L. Williams, R. C. Murphy, and C. C. Leslie. 2010. Pathways regulating cytosolic phospholipase A₂ activation and eicosanoid production in macrophages by *Candida albicans*. *J. Biol. Chem.* 285: 30676–30685.
- Barrett, N. A., O. M. Rahman, J. M. Fernandez, M. W. Parsons, W. Xing, K. F. Austen, and Y. Kanaoka. 2011. Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes. *J. Exp. Med.* 208: 593–604.
- Clarke, D. L., N. H. Davis, C. L. Campion, M. L. Foster, S. C. Heasman, A. R. Lewis, I. K. Anderson, D. J. Corkill, M. A. Sleeman, R. D. May, and M. J. Robinson. 2014. Dectin-2 sensing of house dust mite is critical for the initiation of airway inflammation. *Mucosal Immunol.* 7: 558–567.
- Norimoto, A., K. Hirose, A. Iwata, T. Tamachi, M. Yokota, K. Takahashi, S. Saijo, Y. Iwakura, and H. Nakajima. 2014. Dectin-2 promotes house dust mite-induced T helper type 2 and type 17 cell differentiation and allergic airway inflammation in mice. *Am. J. Respir. Cell Mol. Biol.* 51: 201–209.
- Chu, D. K., A. Llop-Guevara, T. D. Walker, K. Flader, S. Goncharova, J. E. Boudreau, C. L. Moore, T. Seunghyun In, S. Wasserman, A. J. Coyle, et al. 2013. IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization. *J. Allergy Clin. Immunol.* 131: 187–200.e1, 8.

18. Makrinioti, H., M. Toussaint, D. J. Jackson, R. P. Walton, and S. L. Johnston. 2014. Role of interleukin 33 in respiratory allergy and asthma. *Lancet Respir. Med.* 2: 226–237.
19. Tjota, M. Y., C. L. Hrusch, K. M. Blaine, J. W. Williams, N. A. Barrett, and A. I. Sperling. 2014. Signaling through Fc γ -associated receptors on dendritic cells drives IL-33-dependent T_H2-type responses. *J. Allergy Clin. Immunol.* 134: 706–713.e8.
20. Cantley, L. C. 2002. The phosphoinositide 3-kinase pathway. *Science* 296: 1655–1657.
21. Vanhaesebroeck, B., J. Guillermet-Guibert, M. Graupera, and B. Bilanges. 2010. The emerging mechanisms of isoform-specific PI3K signalling. *Nat. Rev. Mol. Cell Biol.* 11: 329–341.
22. Okkenhaug, K., A. Bilancio, G. Farjot, H. Priddle, S. Sancho, E. Peskett, W. Pearce, S. E. Meek, A. Salpekar, M. D. Waterfield, et al. 2002. Impaired B and T cell antigen receptor signaling in p110 δ PI 3-kinase mutant mice. *Science* 297: 1031–1034.
23. Ali, K., A. Bilancio, M. Thomas, W. Pearce, A. M. Gilfillan, C. Tkaczuk, N. Kuehn, A. Gray, J. Giddings, E. Peskett, et al. 2004. Essential role for the p110 δ phosphoinositide 3-kinase in the allergic response. *Nature* 431: 1007–1011.
24. Kuehn, H. S., E. J. Swindle, M. S. Kim, M. A. Beaven, D. D. Metcalfe, and A. M. Gilfillan. 2008. The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells. *J. Immunol.* 181: 7706–7712.
25. Kanaoka, Y., A. Maekawa, J. F. Penrose, K. F. Austen, and B. K. Lam. 2001. Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C₄ synthase. *J. Biol. Chem.* 276: 22608–22613.
26. Hsu, Y. M., Y. Zhang, Y. You, D. Wang, H. Li, O. Duramad, X. F. Qin, C. Dong, and X. Lin. 2007. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. *Nat. Immunol.* 8: 198–205.
27. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rössner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. *J. Immunol. Methods* 223: 77–92.
28. Barrett, N. A., J. M. Fernandez, A. Maekawa, W. Xing, L. Li, M. W. Parsons, K. F. Austen, and Y. Kanaoka. 2012. Cysteinyln leukotriene 2 receptor on dendritic cells negatively regulates ligand-dependent allergic pulmonary inflammation. *J. Immunol.* 189: 4556–4565.
29. Lee, K. S., H. K. Lee, J. S. Haylick, Y. C. Lee, and K. D. Puri. 2006. Inhibition of phosphoinositide 3-kinase δ attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. *FASEB J.* 20: 455–465.
30. Ali, K., M. Camps, W. P. Pearce, H. Ji, T. Rückle, N. Kuehn, C. Pasquali, C. Chabert, C. Rommel, and B. Vanhaesebroeck. 2008. Isoform-specific functions of phosphoinositide 3-kinases: p110 δ but not p110 γ promotes optimal allergic responses in vivo. *J. Immunol.* 180: 2538–2544.
31. Leverrier, Y., K. Okkenhaug, C. Sawyer, A. Bilancio, B. Vanhaesebroeck, and A. J. Ridley. 2003. Class I phosphoinositide 3-kinase p110 β is required for apoptotic cell and Fc γ receptor-mediated phagocytosis by macrophages. *J. Biol. Chem.* 278: 38437–38442.
32. Jackson, S. P., S. M. Schoenwaelder, I. Goncalves, W. S. Nesbitt, C. L. Yap, C. E. Wright, V. Kenche, K. E. Anderson, S. M. Dopheide, Y. Yuan, et al. 2005. PI 3-kinase p110 β : a new target for antithrombotic therapy. *Nat. Med.* 11: 507–514.
33. Parsons, M. W., L. Li, A. M. Wallace, M. J. Lee, H. R. Katz, J. M. Fernandez, S. Saijo, Y. Iwakura, K. F. Austen, Y. Kanaoka, and N. A. Barrett. 2014. Dectin-2 regulates the effector phase of house dust mite-elicited pulmonary inflammation independently from its role in sensitization. *J. Immunol.* 192: 1361–1371.
34. Park, S. J., K. S. Lee, S. R. Kim, K. H. Min, H. Moon, M. H. Lee, C. R. Chung, H. J. Han, K. D. Puri, and Y. C. Lee. 2010. Phosphoinositide 3-kinase δ inhibitor suppresses interleukin-17 expression in a murine asthma model. *Eur. Respir. J.* 36: 1448–1459.
35. Tuveson, D. A., R. H. Carter, S. P. Soltoff, and D. T. Fearon. 1993. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. *Science* 260: 986–989.
36. Okada, T., A. Maeda, A. Iwamatsu, K. Gotoh, and T. Kurosaki. 2000. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. *Immunity* 13: 817–827.
37. Bruyns, E., A. Marie-Cardine, H. Kirchgesner, K. Sagolla, A. Shevchenko, M. Mann, F. Autschbach, A. Bensussan, S. Meuer, and B. Schraven. 1998. T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3- ζ complex, recruits intracellular signaling proteins to the plasma membrane. *J. Exp. Med.* 188: 561–575.
38. Shim, E. K., C. S. Moon, G. Y. Lee, Y. J. Ha, S. K. Chae, and J. R. Lee. 2004. Association of the Src homology 2 domain-containing leukocyte phosphoprotein of 76 kD (SLP-76) with the p85 subunit of phosphoinositide 3-kinase. *FEBS Lett.* 575: 35–40.
39. Shim, E. K., S. H. Jung, and J. R. Lee. 2011. Role of two adaptor molecules SLP-76 and LAT in the PI3K signaling pathway in activated T cells. *J. Immunol.* 186: 2926–2935.
40. Zhu, L. L., X. Q. Zhao, C. Jiang, Y. You, X. P. Chen, Y. Y. Jiang, X. M. Jia, and X. Lin. 2013. C-type lectin receptors Dectin-3 and Dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. *Immunity* 39: 324–334.
41. Orr, S. J., A. R. Burg, T. Chan, L. Quigley, G. W. Jones, J. W. Ford, D. Hodge, C. Razzook, J. Sarhan, Y. L. Jones, et al. 2013. LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN- γ production by repressing β -catenin activation in dendritic cells. *PLoS Pathog.* 9: e1003357.
42. Buczynski, M. W., D. L. Stephens, R. C. Bowers-Gentry, A. Grkovich, R. A. Deems, and E. A. Dennis. 2007. TLR-4 and sustained calcium agonists synergistically produce eicosanoids independent of protein synthesis in RAW264.7 cells. *J. Biol. Chem.* 282: 22834–22847.
43. Kurosaki, T., and S. Tsukada. 2000. BLNK: connecting Syk and Btk to calcium signals. *Immunity* 12: 1–5.
44. Cho, S. H., C. H. Woo, S. B. Yoon, and J. H. Kim. 2004. Protein kinase C δ functions downstream of Ca²⁺ mobilization in Fc ϵ RI signaling to degranulation in mast cells. *J. Allergy Clin. Immunol.* 114: 1085–1092.
45. Xu, S., J. Huo, K. G. Lee, T. Kurosaki, and K. P. Lam. 2009. Phospholipase C γ 2 is critical for Dectin-1-mediated Ca²⁺ flux and cytokine production in dendritic cells. *J. Biol. Chem.* 284: 7038–7046.
46. Gorjestani, S., M. Yu, B. Tang, D. Zhang, D. Wang, and X. Lin. 2011. Phospholipase C γ 2 (PLC γ 2) is key component in Dectin-2 signaling pathway, mediating anti-fungal innate immune responses. *J. Biol. Chem.* 286: 43651–43659.
47. Wills-Karp, M., R. Rani, K. Dienger, I. Lewkowich, J. G. Fox, C. Perkins, L. Lewis, F. D. Finkelman, D. E. Smith, P. J. Bryce, et al. 2012. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. *J. Exp. Med.* 209: 607–622.
48. Verma, A., D. N. Kroetz, J. L. Tweedle, and G. S. Deepe, Jr. 2015. Type II cytokines impair host defense against an intracellular fungal pathogen by amplifying macrophage generation of IL-33. *Mucosal Immunol.* 8: 380–389.
49. Polunuri, S. K., G. G. Jayakar, K. A. Shirey, Z. J. Roberts, D. J. Perkins, P. M. Pitha, and S. N. Vogel. 2012. Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. *J. Immunol.* 189: 50–60.
50. Williams, J. W., M. Y. Tjota, B. S. Clay, B. Vander Lugt, H. S. Bandukwala, C. L. Hrusch, D. C. Decker, K. M. Blaine, B. R. Fixsen, H. Singh, et al. 2013. Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. *Nat. Commun.* 4: 2990.
51. Su, Z., J. Lin, F. Lu, X. Zhang, L. Zhang, N. B. Gandhi, C. S. de Paiva, S. C. Pflugfelder, and D. Q. Li. 2013. Potential autocrine regulation of interleukin-33/ST2 signaling of dendritic cells in allergic inflammation. *Mucosal Immunol.* 6: 921–930.
52. Zhang, L., R. Lu, G. Zhao, S. C. Pflugfelder, and D. Q. Li. 2011. TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. *Int. J. Biochem. Cell Biol.* 43: 1383–1391.
53. Thappali, S. R., K. V. Varanasi, S. Veeraraghavan, S. K. Vakkalanka, and K. Mukkanti. 2012. Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study. *J. Mass Spectrom.* 47: 1612–1619.
54. Plantinga, M., M. Guillems, M. Vanheerswyngheles, K. Deswarte, F. Branco-Madeira, W. Toussaint, L. Vanhoutte, K. Neyt, N. Killeen, B. Malissen, et al. 2013. Conventional and monocyte-derived CD11b⁺ dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. *Immunity* 38: 322–335.
55. Nashed, B. F., T. Zhang, M. Al-Alwan, G. Srinivasan, A. J. Halayko, K. Okkenhaug, B. Vanhaesebroeck, K. T. Hayglass, and A. J. Marshall. 2007. Role of the phosphoinositide 3-kinase p110 δ in generation of type 2 cytokine responses and allergic airway inflammation. *Eur. J. Immunol.* 37: 416–424.
56. Kool, M., M. A. Willart, M. van Nimwegen, I. Bergen, P. Pouliot, J. C. Virchow, N. Rogers, F. Osorio, C. Reis e Sousa, H. Hammad, and B. N. Lambrecht. 2011. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. *Immunity* 34: 527–540.
57. Fruman, D. A., and L. C. Cantley. 2014. Idelalisib—a PI3K δ inhibitor for B-cell cancers. *N. Engl. J. Med.* 370: 1061–1062.